Skip to main content
Fig. 2 | BMC Infectious Diseases

Fig. 2

From: COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center

Fig. 2

Symptom prevalence at baseline vs. D14 and D28+ surveys (N = 199). Among patients who completed the Baseline, D14, and D28+ surveys (N = 199). Follow-up times for the surveys varied. At baseline, no patients reported having the following symptoms: thromboembolism, CKD, palpitations, arthralgia, loss of hearing, need for oxygen, post-exertion polypnea, and rash. CKD chronic kidney disease

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us